Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Bristol-Myers Will Acquire Hepatitis C Firm Inhibitex

by Michael McCoy
January 16, 2012 | A version of this story appeared in Volume 90, Issue 3

In the second hepatitis C drug company acquisition in as many months, Bristol-Myers Squibb has agreed to purchase Inhibitex for about $2.5 billion. Atlanta-based Inhibitex is conducting Phase II clinical trials on INX-189, a small-molecule nucleotide polymerase inhibitor for the treatment of hepatitis C virus (HCV). BMS says the developmental compound will join its own portfolio of antiviral drugs for HCV. Gilead Sciences is in the process of completing the acquisition of Pharmasset, another HCV drug developer, for roughly $11 billion. The HCV drug market heated up earlier in 2011 when FDA approved new HCV treatments from Merck & Co. and Vertex Pharmaceuticals in rapid succession. However, those compounds still need to be taken with PEGylated interferon, an injectable drug associated with fatigue, bone marrow suppression, and anemia. BMS and Gilead are counting on their acquisitions to help them offer all-oral HCV treatment regimens.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.